These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29251737)

  • 1. Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer.
    Bankhead P; Fernández JA; McArt DG; Boyle DP; Li G; Loughrey MB; Irwin GW; Harkin DP; James JA; McQuaid S; Salto-Tellez M; Hamilton PW
    Lab Invest; 2018 Jan; 98(1):15-26. PubMed ID: 29251737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technical note on the validation of a semi-automated image analysis software application for estrogen and progesterone receptor detection in breast cancer.
    Krecsák L; Micsik T; Kiszler G; Krenács T; Szabó D; Jónás V; Császár G; Czuni L; Gurzó P; Ficsor L; Molnár B
    Diagn Pathol; 2011 Jan; 6():6. PubMed ID: 21244664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
    Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
    Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
    Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
    Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Badr NM; Zaakouk M; Zhang Q; Kearns D; Kong A; Shaaban AM
    Histopathology; 2024 Sep; 85(3):437-450. PubMed ID: 38651302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR.
    Caselli E; Pelliccia C; Teti V; Bellezza G; Mandarano M; Ferri I; Hartmann K; Laible M; Sahin U; Varga Z; Lupi C; Stracci F; Sidoni A
    PLoS One; 2021; 16(9):e0255580. PubMed ID: 34555047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Astronomical algorithms for automated analysis of tissue protein expression in breast cancer.
    Ali HR; Irwin M; Morris L; Dawson SJ; Blows FM; Provenzano E; Mahler-Araujo B; Pharoah PD; Walton NA; Brenton JD; Caldas C
    Br J Cancer; 2013 Feb; 108(3):602-12. PubMed ID: 23329232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.
    Laurinaviciene A; Dasevicius D; Ostapenko V; Jarmalaite S; Lazutka J; Laurinavicius A
    Diagn Pathol; 2011 Sep; 6():87. PubMed ID: 21943197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
    Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
    Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
    Li AC; Zhao J; Zhao C; Ma Z; Hartage R; Zhang Y; Li X; Parwani AV
    Breast Cancer Res Treat; 2020 Apr; 180(2):321-329. PubMed ID: 32002765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
    Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
    PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous measurement of breast tumour hormone receptor expression: a comparison of two computational pathology platforms.
    Ahern TP; Beck AH; Rosner BA; Glass B; Frieling G; Collins LC; Tamimi RM
    J Clin Pathol; 2017 May; 70(5):428-434. PubMed ID: 27729430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.
    Pölcher M; Braun M; Tischitz M; Hamann M; Szeterlak N; Kriegmair A; Brambs C; Becker C; Stoetzer O
    Arch Gynecol Obstet; 2021 Sep; 304(3):783-790. PubMed ID: 33585986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies.
    Bolton KL; Garcia-Closas M; Pfeiffer RM; Duggan MA; Howat WJ; Hewitt SM; Yang XR; Cornelison R; Anzick SL; Meltzer P; Davis S; Lenz P; Figueroa JD; Pharoah PD; Sherman ME
    Cancer Epidemiol Biomarkers Prev; 2010 Apr; 19(4):992-9. PubMed ID: 20332278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.
    Sun H; Kang EY; Chen H; Sweeney KJ; Suchko M; Wu Y; Wen J; Krishnamurthy S; Albarracin CT; Ding QQ; Foo WC; Sahin AA
    Breast Cancer Res Treat; 2024 Jun; 205(2):403-411. PubMed ID: 38441847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis.
    Loughrey MB; Bankhead P; Coleman HG; Hagan RS; Craig S; McCorry AMB; Gray RT; McQuaid S; Dunne PD; Hamilton PW; James JA; Salto-Tellez M
    Histopathology; 2018 Aug; 73(2):327-338. PubMed ID: 29575153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Andersen J; Overgaard J
    Acta Oncol; 2008; 47(4):591-9. PubMed ID: 18465327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
    Robertson S; Acs B; Lippert M; Hartman J
    Breast Cancer Res Treat; 2020 Aug; 183(1):161-175. PubMed ID: 32572716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computer Aided Semi-Automated Evaluation of HER2 Immunodetection--A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy.
    Micsik T; Kiszler G; Szabó D; Krecsák L; Hegedűs C; Tibor K; Molnár B
    Pathol Oncol Res; 2015 Sep; 21(4):1005-11. PubMed ID: 25788005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.